Small RNA sequencing data of plasma extracellular vesicles in a breast cancer screening population Authors: Jun-luan Mo, Xi Li, Lin Lei, Xiong-shun Liang, Hong-hao Zhou, Zhao-qian Liu, Li-jun Zhang, Ji-ye Yin, Wen-xu Hong Published: 2024 ABSTRACT The pathogenesis of breast cancer is still unclear. Small RNAs associated with extracellular vesicles (EVs) have been found to be involved in tumor development. It is important to explore the role of EVs small RNAs in breast cancer. In this study, we established a plasma EVS-associated small RNA dataset that included 120 women who were positive for breast cancer screening and 60 women who were negative. These small RNA included 2656 miRNAs, 728 piRNAs, and 154 tsRNAs. These data provide a reference for researchers to explore molecular diagnostic biomarkers for early breast lesions. Background & Summary Breast cancer ranks second in the number of new cancers in the world1. In 2020, it surpassed lung cancer to become the cancer with the highest number of cases in the world2. In 2022, it accounted for 11.6% of all cancer cases worldwide, with 2.34 million new cases1. At present, the etiology and pathogenesis of breast cancer are not completely clear. The prevention and control of breast cancer are still based on early diagnosis and treatment. Therefore, identifying molecular markers of early precancerous lesions has significant social value and scientific significance. EVs are defined as particles that are released from cells, are delimited by a lipid bilayer, and cannot replicate on their own3. Exosomes are one of the three main subgroups of EVs released by mammalian cells, with diameters ranging from 50 to 150 nm4,5. Proteins, RNA, and lipids within exosomes can participate in regulating important cellular physiological activities, including the immune response, apoptosis, angiogenesis, and the inflammatory response. It is believed to be a potential therapeutic target, early diagnostic marker, and targeted drug carrier for various diseases6. Small RNAs mainly include MicroRNAs (miRNAs), PIWI-interacting RNAs (P-element-induced wimpy testis-interacting RNAs, piRNAs), and Transfer RNAs (tRNAs). Small RNAs are involved in important biological processes, such as gene expression and regulation, RNA processing and splicing, protein translation, genetic invasion inhibition, and gametogenesis. It is an indispensable regulatory factor in life activities. MiRNAs are the main component of small RNAs and the main RNA in exosomes. Some miRNAs in exosomes have been proven by cell experiments to be related to the proliferation, differentiation, migration and microenvironment formation of breast cancer cells7–13. PiRNAs are believed to participate in the pathogenesis of tumors by regulating key signaling pathways at the transcriptional or posttranscriptional level14. It is believed that piRNAs participate in the development of breast cancer through DNA methylation15–17. Transfer RNAs are crucial for protein synthesis and are considered not only diagnostic and prognostic indicators but also targets for cancer treatment18. The relationship between tRNA in exosomes and various diseases has been reported, but research on its relationship with breast cancer is extremely rare19. Wang Jingyi reported that the levels of tRF-Ser-TGA-001 and tRF-Ser-TGA-002 in the plasma exosomes of breast cancer patients were significantly lower than those in the plasma exosomes of healthy people. They suggested that tRNA in exosomes might participate in the occurrence of breast cancer20. This study is based on a public health project. The project provides free breast cancer screening for women aged 40–74 who voluntarily participate. Clinical and imaging examinations were also performed. As shown in the research design (Fig. 1), this study selected 180 plasma samples from the project for EVs small RNA sequencing, including 120 positive donors and 60 negative donors. This study described the basic information, reproductive physiology, lifestyle, and disease history of these 180 individuals, as well as a dataset of 2656 miRNAs, 728 piRNAs, and 154 tsRNAs. This study provides valuable resources for transcriptome analysis of small RNAs in EVs. Researchers can use these data to explore the role of EVs small RNAs in breast cancer and find valuable molecular markers.Fig. 1The experimental design and workflow of this study. The experimental design and workflow of this study. Methods and Results Ethical approval The research subjects were sourced from the Urban Cancer Early Diagnosis and Treatment Project, which was approved by the Ethics Committee of the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. The approval number is 15-070/997. The recruitment notice for participants in cancer screening is released by the health management department in the media. Participants register at the community health service center where they reside. The informed consent of participants is obtained through an electronic information system. Only by reading the informed consent form and signing the agreement can be proceed to the next step of the process. Otherwise, her information will not enter the information system, and she will not participate in the next questionnaire survey and breast imaging examination. The informed consent form informs participants that their blood samples and related data may be used for scientific research and publication of papers. All participants signed the informed consent documents. This study is a follow-up to that project, and its research protocol was reviewed and approved by the Ethics Committee of the Shenzhen Center for Chronic Disease Control, with the approval number SZCCC-2020-018-06-PJ. Subjects and sample collection The sample of the study population is from the breast cancer screening project in Shenzhen, a southern city in China. This is a free public health project. Led by the National Cancer Center of China, this study was carried out in multiple cities. This project recruit permanent urban female residents aged between 40 and 74 years to voluntarily participate in questionnaires and breast imaging examinations. Whole blood samples were taken for routine blood analysis, and the remaining plasma samples were frozen for use. The statistical analysis results of the basic information, reproductive physiology information, lifestyle information, and medical history information of the research subjects are shown in the Supplementary Table 1. Breast cancer screening Women aged 45 and older underwent ultrasound examination and X-ray radiography; women under the age of 45 were examined by ultrasound, and X-ray radiography was added if suspicious or positive results were found. Diagnosis by ultrasound and imaging was made by physicians with more than 5 years of working experience. If there were positive lesions, a review by a senior physician was needed. The inspection equipment used was a color ultrasound diagnostic apparatus equipped with a high-frequency linear array probe and a mammography camera with a high-resolution digital acquisition imaging system. Each patient was classified according to the diagnostic criteria established by the American College of Radiology Breast Imaging Reporting and Data System (BI-RADS)21. Extraction and purification of EVs Venous blood was collected from the study population using a 5 ml EDTA blood collection vessel. Whole blood was centrifuged at 3000 rpm at room temperature for 10 min. The supernatant was collected into a 2.0 mL EP tube centrifuge tube, centrifuged at 13000 rpm at 4°C for 10 min, and the supernatant plasma was collected and transferred into 1.5 mL EP tubes with no more than 1 ml per tube. A secondary centrifugation of platelets (the main source of EVs in the blood) was used. After the plasma samples were returned to room temperature, the EVs were separated using a kit. The exoEasy Maxi Kit (QIAGEN Company) was used for the operation. Briefly, a syringe filter was used to filter the plasma to remove more than 0.8 μM particles. One volume of buffer solution (XBP) was added to 1 volume of sample, the test tube was gently inverted 5 times, the mixture was mixed evenly, and the mixture was allowed to rise to room temperature. The XBP mixture was added to an exoEasy centrifuge column and centrifuged at 500 × g for 1 minute. The effluent was discarded, and the column was placed back in the same collection tube. Next, 10 ml of buffer solution XWP was added, and the mixture was centrifuged at 5000 × g for 5 minutes to remove the remaining buffer solution from the column. The flow solution was discarded together with the collection tube, and the centrifuge column was transferred to a new collection tube. Then, 400 μL of buffer XE was added to the membrane, which was subsequently incubated for 1 min and centrifuged at 500 × g for 5 min to collect the eluent. The eluent was subsequently transferred to an exoEasy rotating column membrane, which was subsequently incubated for 1 min and centrifuged at 5000 × g for 5 min to collect the eluent, which was subsequently transferred to an EP tube for storage. Analysis of EVs characteristics Transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA) and flow cytometry (FCM) were used to analyze the characteristics of the extracted EVs. Transmission electron microscopy (TEM) (HT-7700 transmission electron microscope, Hitachi Company, Japan) was used to observe the EVs. The standard operating procedures of the instrument were followed, as described below. A 10 μL EVs sample was added to a copper mesh and allowed to precipitate for 1 minute. Filter paper was used to remove the floating liquid. Next, 10 μL of phosphotungstic acid was dropped onto a copper mesh to precipitate for 1 minute. Filter paper was used to remove the floating liquid. The samples were dried at room temperature for a few minutes. Electron microscopy imaging was performed at 100 kV. Transmission electron microscopy imaging results were obtained, and photos were taken. Figure 2a and b showed that EVs had an independent and complete vesicle structure.Fig. 2Identification of EVs. (a) TEM image of EVs. The ruler is 1 μm. (b) TEM images of EVs. The ruler is 100 nm. (c) Particle size analysis of EVs. The main peak of the particle size is 135 nm. (d) Concentrations of EVs. Each sample was tested three times, and the average of the three tests was taken as the result. Its concentration is 2.02 × 1010 particles mL−1. (e,f) Flow cytometry was used to detect the surface marker protein CD63 on the EVs. NC (blank control) = 100%, and the percentage of CD63-positive cells was 52%. (g,h) Detection of the EVs surface marker protein CD81 by flow cytometry. NC (blank control) = 100%, and the percentage of CD81-positive cells was 81.1%. Identification of EVs. (a) TEM image of EVs. The ruler is 1 μm. (b) TEM images of EVs. The ruler is 100 nm. (c) Particle size analysis of EVs. The main peak of the particle size is 135 nm. (d) Concentrations of EVs. Each sample was tested three times, and the average of the three tests was taken as the result. Its concentration is 2.02 × 1010 particles mL−1. (e,f) Flow cytometry was used to detect the surface marker protein CD63 on the EVs. NC (blank control) = 100%, and the percentage of CD63-positive cells was 52%. (g,h) Detection of the EVs surface marker protein CD81 by flow cytometry. NC (blank control) = 100%, and the percentage of CD81-positive cells was 81.1%. Nanoparticle tracking analysis (NTA) A nanoparticle tracking analysis instrument (NanoSight ns300, Malvern, UK) was used to determine the concentration and particle size of the EVs. EVs were dissolved in 1 mL of filtered PBS, sealed and stored on ice. A disposable clean sample cell was chosen and wiped with dust-free paper against the light to ensure that no particles adhered to the outer tube wall on the optical path. EVs solution was slowly injected while avoiding the formation of bubbles. The sample cell can be moderately tilted and sealed with a lid. The sample pool was placed into the instrument, and the instrument was operated according to standard operating procedures for testing. Experimental conditions for NTA analysis include: Camera Type: sCMOS; Laser Type: Blue488; Camera Level: 13; Slider Shutter: 1232; Slider Gain: 219; FPS: 25.0; Number of Frames: 749; Detect Threshold: 3; Blur Size: Auto. A total of 15 samples were selected for NTA in this study, with an average particle size of 177.56 ± 10.7 nm and an average stock concentration of 3.48 ± 1.4 × 1010 particles mL−1. Figure 2c and d show the NTA results for one of the samples. The average particle size is 170.1 nm, with a main peak at 135 nm and a concentration of 2.02 × 1010 particles mL−1. Flow cytometry (FCM) Flow cytometry (Accuri C6 flow cytometry instrument, BD company, USA) was used to detect surface proteins in the EVs. EVs were dissolved in filtered PBS, divided into 100 μL/tube, sealed and stored on ice. Nonstained EVs were used as negative controls and labeled NC. The sample was stained with two sets of antibodies, CD63 and CD81, which were labeled CD63 and CD81, respectively. Machine testing was performed according to the operating procedures of the flow cytometer instrument. Figure 2e–h show the flow cytometry results of the surface marker proteins CD63 and CD81 in EVs. Total RNA Extraction and Small RNA Sequencing of EVs The total RNA in the EVs was extracted using a kit (QIAGEN exoRNeasy Serum/Plasma Maxi Kit, QIAGEN, No. 77144). The brief operating steps are as follows. One volume of buffer XBP was added to each sample. The test tube was gently inverted 5 times, and the solution was immediately mixed evenly. The sample/XBP mixture was added to the exoEasy rotating column, and the equipment was rotated at a speed of 500 × g for 1 minute. The circulating liquid was discarded, and the chromatographic column was placed back into the same collection tube. Next, 10 mL of XWP was added, and the mixture was rotated at 5000 × g for 5 minutes to wash the column and remove any remaining buffer. The effluent was discarded together with the collection tube. The centrifuge column was transferred to a new collection tube. Then, 700 µl of QIAzol was added to the membrane. The mixture was rotated at 5000 × g for 5 minutes to collect the lysate, which was then transferred to a 2 mL tube. The lysate tube was vortexed for a short period of time and incubated at room temperature (15–25 °C) for 5 minutes. Next, 3.5 µl of miRNeasy Serum/Plasma Spike In Control (1.6 × 108 copies/µl working solution) was added. Then, 90 µl of chloroform was added to the tube containing the cracking solution and covered tightly. The mixture was shaken vigorously for 15 seconds. The mixture was incubated at room temperature (15–25 °C) for 2–3 minutes. The sample was centrifuged at 12000 × g for 15 minutes at 4 °C. The upper aqueous phase was transferred to a new collection tube. Two times the volume of 100% ethanol was added. Immediately transfer up to 700 µl of the sample into a 2 mL collection tube. Centrifuge at room temperature (15–25 °C) at ≥ 8000 × g (≥10000 rpm) for 15 seconds. The fluid was discarded. The centrifugation column steps were repeated for the remaining samples. The fluid was discarded. Next, 700 µl of RWT buffer was added to the RNeasy MinElute centrifuge column. The lid was gently closed, and the sample was centrifuged at ≥ 8000 × g (≥10000 rpm) for 15 seconds. The fluid was discarded. RPE buffer (500 µl) was transferred onto an RNeasy MinElute centrifuge column. The sample was centrifuged at ≥ 8000 × g (≥10000 rpm) for 15 seconds. The fluid was discarded. RPE buffer (500 µl) was transferred onto an RNeasy MinElute centrifuge column. The sample was centrifuged at ≥ 8000 × g (≥10000 rpm) for 2 minutes. The collection tube containing the fluid was discarded. The RNeasy MinElute centrifuge column was placed into a new 2 mL collection tube. The lid of the centrifuge column was opened, and the column was centrifuged at full speed for 5 minutes to dry the membrane. The collection tube containing the fluid was discarded. The RNeasy MinElute centrifuge column was placed into a new 1.5 mL collection tube. Then, 14 µL of RNase-free water was added directly to the center of the centrifuge column membrane. The lid was gently covered, and the column was allowed to stand for 1 min. The column was then centrifuged at full speed for 1 min to elute the RNA. Sequencing Using proprietary digital NGS technology for QIAseq NGS panels, a library was constructed based on the library building strategy of the QIAseq miRNA Library Kit (Qiagen, No. 331502). The NextSeq CN500 sequencing platform in SE75 mode was used for sequencing. 3’ adapter: AACTGTAGGCACCATCAAT. I5 PCR Primer: AATGATACGGCGACCACCGAGATCTACACGTTCAGAGTTCTACAGTCCGA. I7 PCR Primer: CAAGCAGAAGACGGCATACGAGAT[BARCODE]GTGACTGGAGTTCCTTGGCACCCGAGA. A total of 2656 miRNAs, 728 piRNAs, and 154 tsRNAs were analyzed. Data Records All sequencing data have been uploaded to the Gene Expression Integrated Database (GEO) of the National Center for Biotechnology Information (NCBI) in the United States. The accession number is GSE27049722. The dataset contains a metadata spreadsheet of small RNA expression raw data files (in fastq format) and processed data files (raw counts of sequencing reads). Technical Validation EVs validation The effective separation and extraction of EVs is a prerequisite for the accuracy of the data in this study. This study randomly selected 15 samples for EVs sample validation. We used transmission electron microscopy to observe the morphology and size of the EVs. The EVs particle size and concentration were analyzed. Flow cytometry was used to analyze the surface protein markers of the EVs. The analysis results can be found in the EVs identification methods section. Assessment of RNA integrity The OD values of the RNA samples were measured at 260 and 280 nm using a spectrophotometer. A ratio ranging from 1.8–2.0 for A260/A280 was considered acceptable. Sequencing quality control We used Fast-QC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) software to evaluate the overall quality of the sequencing data, including the distribution of mass values of bases, the distribution of mass value positions, the GC content, and the content of base N. Figure 3 shows the data quality chart of one of the samples. Figure 3a shows the quality of the base sequence. The quality scores were all above 20, indicating that the quality of the sequencing data was very good. Figure 3b shows the GC content of the sequence. The actual sequencing GC content distribution curve almost coincided with the theoretical distribution curve, indicating minimal system deviation. Figure 3c shows the quality score for each sequence. The sequencing scores are concentrated in high partitions, indicating good sequencing quality. Figure 3d shows the content of base N. The N% in the diagram is equal to 0, indicating that the sequencer has no unrecognizable bases.Fig. 3Data quality. (a) Base sequence quality. The vertical axis represents the quality score, Q = −10 * log (p). P is the probability of detection error. The horizontal axis represents the position of the sequencing sequence. The blue line is the line connecting the average values of each position. The quality score cannot be lower than 20. The quality scores of these samples were all above 34. (b) Sequence GC content. The red color represents the actual sequencing GC content distribution curve, while the green color represents the theoretical distribution curve. The two curves in the diagram almost completely overlap, indicating that the system deviation is extremely small. (c) Per-sequence quality score. The vertical axis represents the number of reads, and the horizontal axis represents the quality score. A peak value less than 27 is an alarm. The peak value in this example is 36. (d) Base N content. The red line represents the percentage of bases (N%) that the sequencer cannot recognize. Data quality. (a) Base sequence quality. The vertical axis represents the quality score, Q = −10 * log (p). P is the probability of detection error. The horizontal axis represents the position of the sequencing sequence. The blue line is the line connecting the average values of each position. The quality score cannot be lower than 20. The quality scores of these samples were all above 34. (b) Sequence GC content. The red color represents the actual sequencing GC content distribution curve, while the green color represents the theoretical distribution curve. The two curves in the diagram almost completely overlap, indicating that the system deviation is extremely small. (c) Per-sequence quality score. The vertical axis represents the number of reads, and the horizontal axis represents the quality score. A peak value less than 27 is an alarm. The peak value in this example is 36. (d) Base N content. The red line represents the percentage of bases (N%) that the sequencer cannot recognize. We constructed sequence length distribution maps (as shown in Fig. 4a) and GC content distribution maps (as shown in Fig. 4b) for each sample. Mapping is a commonly used method for genome assessment. We use the internationally recognized BWA algorithm to perform mapping analysis on each sample. The mapping analysis results of all the samples are shown in the Supplementary Table 2. The base statistical analysis data of all samples are shown in the Supplementary Table 3.Fig. 4RNA sequence quality analysis. (a) The length distribution of all small RNAs in one sample. (b) Analysis of base preference for all small RNAs in one sample. (c,d) MiRNA analysis. (c) The length distribution of small RNA sequences aligned to miRBase. (d) Perform base preference analysis on reads compared to the miRBase database. (e,f) PiRNA analysis. (e) The length distribution of novel piRNAs with small RNAs that can be aligned to piRNA clusters but without corresponding annotations in NCBI. (f) The base preference results of novel piRNAs. (g,h) TsRNA analysis. (g) The length distribution of the aligned small RNA sequences in the tRFdb and MINTBase databases. (h) The base preference results of small RNA alignment to sequences in the tRFdb and MINTBase databases. RNA sequence quality analysis. (a) The length distribution of all small RNAs in one sample. (b) Analysis of base preference for all small RNAs in one sample. (c,d) MiRNA analysis. (c) The length distribution of small RNA sequences aligned to miRBase. (d) Perform base preference analysis on reads compared to the miRBase database. (e,f) PiRNA analysis. (e) The length distribution of novel piRNAs with small RNAs that can be aligned to piRNA clusters but without corresponding annotations in NCBI. (f) The base preference results of novel piRNAs. (g,h) TsRNA analysis. (g) The length distribution of the aligned small RNA sequences in the tRFdb and MINTBase databases. (h) The base preference results of small RNA alignment to sequences in the tRFdb and MINTBase databases. MiRNA analysis The size of the miRNA is approximately 17–24 bp. MiRNAs are ultimately formed through a series of processing processes, such as transcription and enzymatic cleavage, within cells. They are first transcribed into pri miRNAs by RNA polymerase, then cleaved into pre-miRNAs with hairpin structures by the endonuclease Drosha, and finally further cleaved by Dicer to form mature miRNAs. In the miRNA analysis section, we compared the filtered clean reads to the miRNA database of the corresponding species to obtain the expression of miRNAs. In addition, the filtered clean reads were compared to the Rfam database of the corresponding species. Figure 4c shows the length distribution of the reads compared to those in the miRBase database. As shown in Fig. 4d base preference analysis will be performed on reads compared to the miRBase database. PiRNA analysis Piwi-interacting RNA (Piwi) is a type of small noncoding RNA with a length of approximately 24–33 bp that can bind to Piwi proteins and exert biological functions. Within the genome, piRNAs are mainly distributed in clusters, forming piRNA clusters. Because piRNAs mainly originate from piRNA clusters, in the process of data analysis, sequences with a length range of 24–33 bp were selected from sequences that were not aligned to miRBase and aligned to piRNA clusters (derived from the piRNA cluster database) to obtain potential piRNAs. Known piRNA data from the NCBI database, including ID number and sequence information, were obtained, the analyzed potential piRNAs were annotated, and known piRNA cluster source piRNAs (known piRNAs) were obtained. Among them, the sequences that can be compared to piRNA clusters but do not have corresponding annotations in NCBI are new piRNAs (novel piRNAs). At the same time, from sequences with a length range of 24–33 bp that have not been aligned to the piRNA cluster, sequences that can be aligned to both the rRNA database and the piRNA database (NCBI) or sequences that can be aligned to both the GtRNA database and the piRNA database (NCBI) were selected as rRNA-derived piRNAs and tRNA-derived piRNAs, respectively. Figure 4e shows the length distribution of novel piRNAs with small RNAs that can be aligned to piRNA clusters but without corresponding annotations in NCBI. Figure 4f shows the base preference results for the novel piRNAs. TsRNA analysis TsRNAs are small noncoding RNAs derived from tRNAs. Some of them are formed during the maturation process of tRNA, while the rest are produced by special enzymes after the mature secondary structure of tRNA is formed. In the analysis of tsRNAs, the sequences that were not aligned to miRBase (12–23 bp, 34–43 bp) or the piRNA cluster (24–33 bp) were first compared for rRNA. After the sequences that could be aligned with rRNA were filtered out, those that were 24–33 bp in length and could be aligned with the GtRNA database and piRNA database (NCBI) were filtered out. The remaining sequences were aligned to the tRFdb and MINTBase databases to determine the expression of the tsRNAs. Figure 4g shows the length distribution of the aligned small RNA sequences in the tRFdb and MINTBase databases. Figure 4h shows the base preference results of small RNA alignment to sequences on tRFdb and MINTBase. Research limitation The RNA found in EVs can be either on the surface of the vesicle or inside it. The RNA on the surface of the vesicle is part of the membrane structure, while the RNA inside the vesicle may have been transferred from the source cell23,24. In this study, we did not use RNAase to pretreat EV preparations. Therefore, it is not possible to determine whether the detected small RNA comes from the surface or the interior of the vesicle. It is also not possible to rule out the possibility that the detected RNA comes from free-circulating RNA contaminants that were jointly separated during the preparation process. So the data set should be considered as RNA associated with EVs. Supplementary information Supplementary Table 2 Supplementary Table 3 Supplementary Table 1 Supplementary Table 2 Supplementary Table 3 Supplementary Table 1